Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/81 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME16389570
PMID: | 16389570
LR: | 20061115
CED: | 20060103
DCO: | 20060207
Autoren: | Lu-Suguro JF; Hua J; Sakamoto K; Nagaoka I
Titel: | Inhibitory action of glucosamine on platelet activation in guinea pigs.
Quelle: | Inflammation research : official journal of the European Histamine Research Society ... [et al.]; VOL: 54 (12); p. 493-9 /200512/
PM: | Print
SU: | IM
Sprache: | English
CY: | Switzerland
JID: | 9508160
ISSN: | 1023-3830
CO: | INREFB
Institution: | Department of Host Defense and Biochemical Research, Juntendo University, School of Medicine, 2-1-1 Hongo, Tokyo 113-8421, Japan.
DT: | Journal Article; Research Support, Non-U.S. Gov't
Schlagwörter
CT: | ADENOSINE DIPHOSPHATE/metabolism; ADENOSINE DIPHOSPHATE/pharmacology; ADENOSINE TRIPHOSPHATE/metabolism; ADMINISTRATION, ORAL; ANIMALS; BLEEDING TIME; BLOOD PLATELETS/*drug effects; BLOOD PLATELETS/metabolism; BODY WEIGHT/drug effects; CYTOPLASMIC GRANULES/secretion; FEMALE; GLUCOSAMINE/administration & dosage; GLUCOSAMINE/*pharmacology; GUINEA PIGS; PLATELET ACTIVATION/*drug effects; PLATELET AGGREGATION/drug effects; PLATELET COUNT; RECEPTORS, PURINERGIC P2/metabolism; THROMBOXANE A2/metabolism
CTG: | ADENOSINDIPHOSPHAT/Stoffwechsel; ADENOSINDIPHOSPHAT/Pharmakologie; ADENOSINTRIPHOSPHAT/Stoffwechsel; APPLIKATION, ORALE; TIER; BLUTUNGSZEIT; THROMBOZYTEN/*Arzneimittelwirkungen; THROMBOZYTEN/Stoffwechsel; KÖRPERGEWICHT/Arzneimittelwirkungen; ZYTOPLASMATISCHE GRANULA/Sekretion; WEIBLICH; GLUCOSAMIN/Verabreichung & Dosierung; GLUCOSAMIN/*Pharmakologie; MEERSCHWEINCHEN; THROMBOZYTENAKTIVIERUNG/*Arzneimittelwirkungen; THROMBOZYTENAGGREGATION/Arzneimittelwirkungen; THROMBOZYTENZÄHLUNG; REZEPTOREN, PURINERGE P2-/Stoffwechsel; THROMBOXAN A2/Stoffwechsel
TE: | Receptors, Purinergic P2; Glucosamine/3416-24-8; Adenosine Triphosphate/56-65-5; Thromboxane A2/57576-52-0; Adenosine Diphosphate/58-64-0
CR: | 3416-24-8; 56-65-5; 57576-52-0; 58-64-0
AB: | OBJECTIVE: Glucosamine, a naturally occurring amino monosaccharide, has been used to treat or prevent osteoarthritis in humans. Recently, we have revealed that glucosamine inhibits platelet activation in vitro. However, the effect of in vivo administration of glucosamine has not yet been clarified. In this study, we administered glucosamine orally to guinea pigs and examined its effects on platelet functions. MATERIALS AND METHODS: Glucosamine hydrochloride solution (0.5%, 5 mg/ml) was administered orally to guinea pigs ad libitum for 22 days, and platelet rich plasma was collected to evaluate platelet functions in vitro. Guinea pigs received an average of 400 mg glucosamine/animal/day. RESULTS: Glucosamine-administration suppressed platelet aggregation in response to ADP by 51% (p < 0.01), but not platelet aggregation induced by collagen. Furthermore, glucosamine-administration inhibited the ADP-induced extracellular release of ATP and production of thromboxane A(2) by 91% and 96%, respectively (p < 0.001). In contrast, glucosamine did not affect the body-weights, platelet counts and bleeding time in guinea pigs after the administration. CONCLUSIONS: These observations suggest that glucosamine is likely to exert an inhibitory action on platelets in vivo by suppressing platelet aggregation, ATP release, and thromboxane A(2) production. Thus, glucosamine could be expected as a novel and safe anti-platelet agent.

» Volltext »
» Fenster schließen »